Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 16;2(1):vdaa006. doi: 10.1093/noajnl/vdaa006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 3 — Monitoring pharmacologic inhibition of SIRT1 with 2-[¹⁸F]BzAHA PET/CT/MRI. (A) Representative coronal T2-weighted MRI and 2-[¹⁸F]BzAHA PET/CT/MR images depicting different regions of the rat brain with intracerebral 9L tumor (shown by a dotted line on a side-view of a 3D rendered image): through the area of the hippocampus (Hippo, top), 9L tumor (9L, middle), nucleus accumbens (NA, bottom). 2-[¹⁸F]BzAHA PET/CT images were obtained at 20 min post-radiotracer administration before (baseline) and after treatment with either EX-527 (SIRT1 selective inhibitor) or MC1568 (HDAC class IIa selective inhibitor). PET/CT images are color-coded to standard uptake values (SUVs). The levels of 2-[¹⁸F]BzAHA-derived radioactivity are expressed as (B) SUVs or (C) distribution volumes (DVs) in 9L tumors and different brain structures at baseline (N = 4) and after therapy with EX-527 (N = 3) or MC1568 (N = 3). Data—mean ± SEM. Statistical significance was determined using ANOVA for repeated measures; ****P < .0001.